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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common 
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Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths 
in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 
selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy 
for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery 
of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a 
highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from 
portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT 
with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and 
has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, 
it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various 
clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the 
outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines 
as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma.
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primary liver cancer and is the second most common cause 
of death from cancer worldwide, with an estimated 745000 
deaths in 2012 (1). It is the fifth most common cancer 
among men (554000 cases) and the ninth most common 
cancer in women (228000) (1). The age-adjusted worldwide 
incidence rates per 100000 for men and women are 15.3 
and 5.3, respectively (1). In men, the incidence rates 
are highest in Eastern and South-Eastern Asia (31.9 and 
22.22, respectively), intermediate in Southern Europe (9.5) 
and Northern America (9.3), and the lowest in Northern 
Europe (4.6) and South-Central Asia (3.7) (1). In women, 
the rates are generally lower than those in men with the 
highest rates in Eastern Asia and Western Africa (10.2 and 
8.1, respectively) and the lowest in Northern Europe and 
Micronesia/Polynesia (1.9 and 1.4, respectively) (1). In the 
United States, an estimated 23000 deaths from liver cancer 
http://dx.doi.org/10.3348/kjr.2016.17.4.472
pISSN 1229-6929 · eISSN 2005-8330
Review Article | Intervention
473
Y90-SIRT for HCC Treatment
Korean J Radiol 17(4), Jul/Aug 2016kjronline.org
safety, efficacy, and Sorafenib (Table 1). Ongoing and 
completed clinical trials were identified through searches of 
clinical trial databases (6). Study eligibility was assessed by 
a single investigator in an un-blinded manner. Studies were 
retained if they met the following criteria: 1) TheraSphere® 
or glass microspheres use in the treatment for HCC, 2) effect 
of Y90-SIRT with glass microspheres on early, intermediate 
or advanced HCC, or 3) safety and/or efficacy of Y90-SIRT 
with glass microspheres or Sorafenib for HCC. All study 
designs were accepted. Studies were excluded if their 
aim was to evaluate: 1) SIR-Spheres® or 2) resin-based 
microspheres as our main focus in this literature review 
was the treatment of HCC with glass microspheres which 
is currently approved by the Food and Drug Administration 
(FDA) under an humanitarian device exemption (HDE).
Yttrium-90 Selective Internal Radiation 
Therapy (Y90-SIRT)
The technique uses Y90 impregnated glass or resin 
microspheres, which are delivered through a catheter 
directly into the hepatic arteries (7, 8). It takes advantage 
of the fact that primary and secondary hepatic tumors are 
vascularized mostly by arterial blood flow in comparison 
to healthy liver parenchyma which obtains its blood supply 
mainly from portal venous blood (7). The diameters of the 
glass and resin microspheres (20–30 microns versus 20–60 
microns, respectively) allow them to become permanently 
embolized in the terminal arterioles of tumor (9). Y90 
is a pure beta-emitter that disintegrates into stable 
zirconium-90 and has a half-life of 64.24 ± 0.30 hours 
(7, 8, 10). The average β-emission is 0.9367 MeV, with a 
mean tissue penetration of 2.5 mm and a maximum tissue 
penetration of 10 mm (7, 8). This allows delivery of high 
radiation doses to hepatic tumors while minimally affecting 
the healthy surrounding liver parenchyma unlike external 
radiation (3, 7, 11). 
There are two commercially available microspheres: 
occurred in 2014 (2). In this same year, an estimated 33190 
new cases of liver cancer were expected (2). From 2006 to 
2010, the rates of liver cancer increased by 3.7% per year 
in men and by 2.9% per year in women (2).
Hepatocellular carcinoma has a poor prognosis with an 
overall 5-year relative survival rate of 16% and survival 
decreases as patients are diagnosed with regional and 
distant stages of the disease (2). Only 41% of liver cancer 
patients are diagnosed at an early stage, while the majority 
of patients present with advanced disease. Curative 
treatments indicated for early HCC include resection, liver 
transplantation, and percutaneous ablation (3, 4). Patients 
with early HCC can achieve a survival rate of 50–70% at 
5 years after undergoing resection, liver transplantation, 
or percutaneous ablation (5). Non-curative treatments 
to improve survival in patients with unresectable HCC 
include locoregional therapies such as transarterial 
chemoembolization (TACE) and selective internal radiation 
therapy (SIRT) for intermediate HCC and sorafenib for 
advanced HCC (3, 4).
Methods
A systematic literature search for yttrium-90 (Y90)-SIRT 
with glass microsphere studies (published, unpublished 
and ongoing) was carried out from August 19, 2014 to 
July 19, 2015, and it was updated on August 30, 2015. 
Two investigators developed and conducted the literature 
search. Studies were identified using database searches 
and citation searches of selected articles. The electronic 
database searched was PubMed (1965-present). Only 
articles in English were selected for the review and no date 
restrictions were applied to the search. The search was 
conducted using free-text terms and standardized subject 
terms appropriate for the specific database. Combinations of 
the following search terms were used: HCC, hepatocellular 
carcinoma, radioembolization, TARE, SIRT, Yttrium-90, Y90-
SIRT, TheraSphere®, glass microspheres, therapy/treatment, 
Table 1. Summary of Search Strategy for PubMed
Search Strategy Search Terms (Combined with AND/OR)
1
HCC AND (radioembolization OR TARE OR SIRT)
(HCC therapy OR treatment) AND (TARE OR Y90 OR Yttrium-90)
Hepatocellular carcinoma AND (TARE OR Y90 OR Y90-SIRT OR radioembolization)
HCC OR hepatocellular carcinoma
2
HCC AND safety and/or efficacy of (Y90-SIRT OR Y90 OR TheraSphere® OR glass microspheres OR Sorafenib) 
  (3, 6, 11, 24, 34, 43, 47, 48, 61-63, 66-69, 74)
HCC = hepatocellular carcinoma, TARE = transarterial radioembolization, Y90-SIRT = yttrium-90 selective internal radiation therapy
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TheraSphere® (MDS Nordion, Ottawa, Canada) and SIR-
Spheres® (Sirtex Medical Ltd., Lane Cove, Australia) 
(8). In 1999, the United States FDA approved the glass 
microspheres (TheraSphere®), under an HDE, for radiation 
treatment or as a neo-adjuvant to surgery or transplantation 
in patients with unresectable HCC who could have 
placement of appropriately positioned hepatic arterial 
catheters, and later it approved the use of TheraSphere® 
in patients with portal vein thrombosis (12). The FDA 
approved the use of resin microspheres (SIR-Spheres®) in 
2002 via a premarket approval for its use in the treatment 
of unresectable metastatic colorectal cancer to the liver 
with adjuvant chemotherapy with floxuridine (13).
Pre-Treatment Evaluation 
Prior to undergoing Y90-SIRT, patients must undergo 
pre-treatment evaluation to ensure that the therapy is 
successful (14, 15). This pre-treatment evaluation is 
performed 1–2 weeks prior to the procedure and it consists 
of the following studies: clinical studies, laboratory tests, 
and imaging (triphasic liver CT or MRI, angiography, and a 
technetium-99m labeled macroaggregated albumin [99mTc-
MAA] scan) (14, 16).
Clinical Evaluation
The clinical evaluation is performed by a multidisciplinary 
team which determines a patient’s candidacy for Y90-
SIRT. The multidisciplinary team may consist of the 
following specialists depending on the local practices in 
the institution involved: surgical/medical oncologists, 
transplant surgeons, hepatologists, radiologists, and 
interventional radiologists (14). During the clinic visit, 
evaluation of a patient’s performance status per the The 
Eastern Cooperative Oncology Group (ECOG) is completed 
(14). Patients with elevated baseline bilirubin (> 2 mg/
dL), a Child-Pugh class C (score ≥ 10), an ECOG performance 
status ≤ 2, and an estimated radiation dose to the lungs > 
30 Gy in a single treatment or 50 Gy in multiple treatments 
are not considered ideal candidates for Y90-SIRT (9, 14).
 
Laboratory Tests
Patients with HCC undergo laboratory tests that include 
liver function tests, tumor markers, serum bilirubin, serum 
albumin, and the prothrombin time (PT)/the international 
normalized ratio (14). Patients with cirrhosis are classified 
based on the commonly used Child-Pugh classification 
which includes an assessment of encephalopathy and 
ascites in addition to the laboratory tests.
Imaging Evaluation
Triphasic Liver CT or MRI
The imaging evaluation consists of triphasic liver CT or 
MRI to evaluate variant vascular anatomy and to assess 
the extent and location of the hepatic tumor and its 
hypervascularity (7, 14). CT scans may identify several 
characteristics of primary HCC that are associated with 
a favorable response to Y90-SIRT such as well-defined 
tumor margins, central hypervascularity pattern, and 
hepatopulmonary fraction (17).
Angiography
Angiography is useful for arterial mapping as it provides 
the interventional radiologist with an assessment of the 
hepatic arterial anatomy, variant vasculature, and patency 
of the portal vein (14). It is also helpful for the occlusion 
of extrahepatic arteries, which supply the liver, with coil 
embolization (7, 14). Some extrahepatic arterial branches 
that may be coil embolized prior to therapy are: GDA, 
RGA, accessory left gastric artery, cystic artery, falciform 
ligament artery, phrenic arteries, inferior esophageal 
artery, supraduodenal artery, and retroduodenal artery 
(7, 14, 18, 19). These extrahepatic arterial branches are 
occluded prior to radioembolization to reduce extrahepatic 
diffusion of the microspheres which can result in significant 
side effects and/or to minimize delivery of only partial 
treatment during administration of the microspheres via 
the main hepatic vessel (7, 14). Between 17% to 30.8% 
of liver tumors and, in particular HCC, receive their blood 
supply from extrahepatic arterial branches (7). Development 
of extrahepatic branches can result from a history of 
chemoembolization, exophytic tumors, and occlusion of the 
main arterial pedicle and size of the tumor volume. In 63% 
of the tumors with development of extrahepatic branches, 
tumor size was larger than 6 cm (7).
Two commonly occluded extrahepatic arteries are the 
GDA and the RGA (7, 20). The GDA which branches off 
the common hepatic artery can be identified on CT and 
arteriography and is occluded by coiling (hydrocoils or 
metal coils) prior to the treatment as reflux carries a risk 
of pancreatitis and gastroduodenal ulceration (7). The 
study by Vesselle et al. (7) recommends that the GDA 
should be occluded as proximal as possible as extrahepatic 
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branches may arise very early and that collateral branches 
should also be occluded. However, occlusion of the GDA 
is contraindicated in the presence of a retrograde flow as 
there is no benefit and it may prove harmful to the patient 
(7). Another commonly occluded artery is the RGA, which 
arises from the main hepatic artery in 45–57% of patients 
(7). Catheterization of the RGA can prove to be technically 
difficult due to its narrow diameter, tight anatomical 
angle, and anatomical variants (7). In addition to using a 
microcatheter, a detachable hydrocoil or remodeling balloon 
can be used (7).
 
Technetium-99m Labeled Macroaggregated Albumin 
(99mTc-MAA) Scan
Prior to treatment, the patient must also undergo a 99MTc-
MAA scan to assess pulmonary and splanchnic shunting and 
to confirm that there is no extrahepatic uptake (7, 14). A 
mixture of albumin particles similar to the size of the glass 
microspheres (25–35 microns) are bound to the gamma-
emitting radioisotope 99mTc (21). The albumin particles 
are then imaged via single photon emission computed 
tomography gamma camera scintigraphy to detect shunting 
and determine the lung shunt fraction (LSF) (21). The LSF 
is used to calculate the appropriate dose that should be 
delivered to the lungs in an attempt to minimize the risk of 
radiation pneumonitis (9).
 
Dose Calculation for TheraSphere® (22-24)
To determine the liver volume for which the Y90 glass 
microspheres are delivered (i.e., volume of distribution) a 
3-dimensional reconstruction of the target site is performed 
using CT or MR imaging. To calculate the mass of infused 
liver tissue (in kg), a conversion factor of 1.03 g/cm3 
is used. The required activity for injection and the dose 
delivered to the target are calculated by the following 
formula:
A (in GBq) = (D [in Gy] x M [in kg]) / 50
Where A is the net TheraSphere® activity delivered to the 
liver, D is the dose administered to the target liver mass, 
and M is the target liver mass.
When the LSF and residual activity (R) in the vial after 
treatment are taken into account, the actual dose delivered 
to the target mass (Gy) is calculated by the following 
formula:
D (in Gy) = {A (in GBq) x 50 x (1 - [LSF - R])} / M (in kg)
Procedure
After pre-treatment evaluation, the patient will undergo 
Y90-SIRT which is done on an outpatient basis (21). 
Under fluoroscopic guidance, glass microspheres (about 
1–8 million glass spheres) are delivered to the liver via 
a catheter placed into the femoral artery, which is then 
guided into the hepatic artery and eventually positioned 
into the diseased lobe/segment of the liver by following 
the branch of the hepatic artery (21). Once the catheter is 
properly positioned, the microspheres are infused at a rate 
similar to that of the hepatic arterial flow over a period 
of 3–5 minutes (9). Delivery of the glass microspheres is 
dependent on the hepatic arterial flow distal to the catheter 
tip. It is necessary to ensure that the catheter does not 
occlude the vessel in which it is positioned in order to 
prevent reflux secondary to vessel spasm (9).
Post-Treatment Assessment
After patients receive their treatment, they undergo post-
treatment imaging and laboratory evaluation to assess the 
response to treatment or lack thereof. Y90-SIRT is associated 
with low toxicity and patients who receive an administered 
activity of less than 3 GBq can be released without contact 
restrictions according to the Nuclear Regulatory Commission 
contact scenario (25). The time interval for obtaining post-
treatment imaging and laboratory evaluation varies among 
authors and clinical institutions (20). The study by Riaz, 
Awais, and Salem obtained triphasic CT or MRI at 1 month 
following treatment and at 3 month intervals following 
the first post-treatment as it may take 3–6 months for the 
optimal response (size reduction) to occur (14). Laboratory 
studies obtained 1 month following Y90-SIRT include liver 
function studies, complete blood count and tumor markers 
(alpha-fetoprotein for HCC) (14).
Tumor Response Assessment Following  
Y90-SIRT 
Tumor response assessment following Y90-SIRT can be 
performed with conventional cross-sectional imaging such 
as CT and MRI (9, 17). There is a lack of standardization of 
functional imaging in HCC and response assessment based 
on anatomical methods is considered as the standard (26, 
27).
Four commonly used guidelines to assess tumor response 
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following therapy are: World Health Organization (WHO) 
(28) (bidimensional), Response Evaluation Criteria in 
Solid Tumors (RECIST) (29) (unidimensional), Modified 
Response Evaluation Criteria in Solid Tumors (mRECIST) 
(30) (unidimensional), and the European Association for 
the Study of the Liver (EASL) (31) (necrosis). The RECIST 
guideline was amended in 2010 to become the mRECIST 
(30). The mRECIST adopted the concept of viable tumor, 
which shows arterial enhancement on contrast-enhanced 
radiologic imaging techniques, thus enabling an evaluation 
of the tumor response after therapeutic strategy (30). The 
EASL guidelines address the limitations of the guidelines 
of the WHO and RECIST, which based their guidelines on 
systemic therapies resulting in limitations when applied to 
locoregional therapies such as Y90-SIRT (31). 
The study by Rhee et al. (32) showed that diffusion-
weighted imaging (DWI) functional MR may assist in early 
determination of the response or failure of Y90-SIRT in 
HCC. Unlike MR anatomic imaging studies which are able 
to assess tumor response until 3 months after treatment, 
DWI showed that imaging changes at 1 month preceded 
anatomic size changes seen at 3 months following Y90-SIRT 
(32). Earlier detection would allow for repeat treatment 
or alternative therapy such as TACE to be given sooner to 
patients rather than waiting 3 months to determine the 
treatment response (32).
In an effort to better identify the tumor response and 
therapy-related changes in serum markers after Y90-SIRT, 
a retrospective single-center study assessed the tumor 
response by using the RECIST 1.1, mRECIST, and Choi 
criteria (33). Using these three guidelines in addition to the 
model for end stage liver disease and the serum C-reactive 
protein, the study was able to create a prognostic model 
which could predict survival probability for individual 
patients as early as one month after treatment (33). 
However, this prognostic model needs to be validated 
further by performing larger prospective treatment studies. 
Complications
Although studies have shown that Y90-SIRT can be 
considered a safe and efficacious treatment for HCC, 
complications associated with the therapy can occur 
(Table 2) (34). Some patients may experience a post-
radioembolization syndrome (PRS) which consists of 
nausea, vomiting, fatigue, abdominal pain/discomfort, 
and/or cachexia (14). Hospitalization is rarely required and 
the incidence of PRS ranges from 10% to 70% (14, 35). 
Extrahepatic microsphere delivery or radioactivity affecting 
surrounding structures can result in hepatic dysfunction, 
biliary system complications, radiation pneumonitis, 
gastrointestinal (GI) complications, acute pancreatitis, 
radiation dermatitis, and lymphopenia (14). Other 
complications include: thrombocytopenia, vascular injury, 
contrast-induced nephrotoxicity, and allergic reaction to 
iodinated contrast media (14).
A serious hepatic complication after Y90-SIRT is 
radiation-induced liver disease (RILD) (14). The incidence of 
RILD ranges from 0% to 4% and it occurs due to radiation 
exposure of healthy hepatic parenchyma (14, 36, 37). 
Clinically, patients develop hepatomegaly, ascites, jaundice 
and elevated serum transaminases, especially alkaline 
phosphatase (37). Treatment involves aggressive therapy 
to control symptoms of abdominal ascites (37). Sangro et 
al. (38) further described radioembolization-induced liver 
disease (REILD) in 20% of patients who had undergone 
chemotherapy either before or after radioembolization. 
Patients with REILD presented clinically with jaundice and 
ascites as late as 1 to 2 months post-radioembolization. 
Post-radioembolization biliary complications include 
radiation cholecystitis (may be prevented by identifying 
and coiling the cystic artery (18, 19)), radiation-induced 
cholangitis, and bilomas/abscess (14). The incidence of 
post-radioembolization biliary complications is less than 
10% and patients with prior surgeries involving the ampulla 
of Vater have a higher risk (14, 39). Less than 1% of 
patients will present with radiation pneumonitis and it is 
recommended that delivery of Y90 to the lungs should be 
less than 30 Gy in one treatment or the cumulative dose 
should be less than 50 Gy in multiple treatments (40). 
Patients with GI complications may present with diarrhea 
or ulcers. GI ulcers occur in less than 5% of patients and 
prophylactic coil embolization of the GDA and the RGA 
may help prevent sequelae (7, 14, 41). Acute pancreatitis 
may present with severe epigastric pain and with elevated 
serum lipase and amylase levels (14). Although diffusion 
of microspheres in the extrahepatic arteries such as the 
falciform artery is rare, it may result in radiation dermatitis 
with periumbilical pain (7, 14). Patients may have a greater 
than 25% decrease in their lymphocyte count following Y90-
SIRT without an increase in the incidence of opportunistic 
infections (11, 14, 34).
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Table 2. Summary of Post-Y90 SIRT Complications (11, 14, 35-37, 39-41, 75)
Complications Findings/Conclusions Incidence Prevent/Treatment
Hepatic Hepatic  
  dysfunction
RILD Hepatomegaly, ascites,  
  jaundice, elevated serum  
  transaminases (esp. alkaline  
  phosphatase) 
0–4% 
  (36, 37) 
May require aggressive therapy to  
  control symptoms from  
  abdominal ascites
REILD (36) Jaundice and ascites 1 to 2  
  months after RE/observed  
  in patient that had received  
  chemotherapy pre- or post-RE
20% (36) Systematically assess for liver  
  damage 1 to 2 months after RE
Extrahepatic    GI PRS Nausea, vomiting, fatigue,  
  abdominal pain/discomfort,  
  and/or cachexia
10–70%  
  (14, 35) 
Antiemetics for nausea, vomiting;  
  steroids
GI ulcers < 5% (41) May prevent by coiling GDA and  
  right gastric artery/prophylactic  
  antacids; endoscopy to confirm
RUQ pain or generalized 
  abdominal pain
Over-the-counter analgesics
Diarrhea Antidiarrheal medications; fluids  
  and electrolyte replacement
Biliary Radiation cholecystitis < 10% (39) May prevent by coiling cystic artery
Radiation-induced  
  cholangitis
Fever, jaundice, RUQ May require antibiotics
Bilomas/abscess Conservative management/ 
  percutaneous drainage
Pancreatic Acute pancreatitis Severe epigastric or  
  periumbilical pain
Very rare  
  (14) 
Conservative treatment
Pulmonary Radiation pneumonitis May see bat-wing appearance  
  on chest CT
< 1%  
  (40, 75) 
Recommend delivery of Y90 to  
  lungs < 30 Gy in one treatment  
  or accumulative dose < 50 Gy in  
  multiple treatments (11, 40)
Atelectasis and/or  
  pleural effusion
May require steroids
Renal Contrast-induced  
  nephrotoxicity
May prevent by adequate hydration 
  pre- and post-procedure and  
  limited use of iodinated contrast
Vascular Vascular injury May prevent by stopping blood  
  thinners appropriately
Radiation dermatitis  
  and periumbilical pain
Diffusion of microspheres in  
  falciform artery
Rare (14) May prevent by coiling artery
Hematology Lymphopenia Patients may have greater than 
  25% of their lymphocyte  
  count decrease following  
  Y90-SIRT
Thrombocytopenia Splenomegaly may be observed
Immunology Allergic reaction to  
  iodinated contrast
Range from pruritic rash to  
  anaphylactic shock
May require anti-histamine and/ 
  or steroids
GDA = gastroduodenal artery, GI = gastrointestinal, PRS = post-radioembolization syndrome, RE = radioembolization, REILD = 
radioembolization-induced liver disease, RLD = radiation-induced liver disease, RUQ = right upper quadrant, Y90-SIRT = yttrium-90 
selective internal radiation therapy
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Y90-SIRT Outcomes
The majority of published studies on the treatment of 
HCC patients with Y90-SIRT are retrospective or small, non-
controlled prospective studies, and therefore, they are 
only supported by level II-2 and II-3 evidence (42). There 
is a lack of large, randomized, controlled trials (Table 3). 
Studies have reported improved median survival in patients 
with intermediate- to advanced-stage HCC following Y90-
SIRT (median 7–41.6 months) (24, 38, 43, 44). Objective 
response rates vary between 35–70% among studies 
depending on the guideline criteria used (24, 38, 44, 45). 
Approximately 20% of patients present with liver-associated 
toxicity and treatment-related deaths are estimated to 
occur in about 3% of patients (46).
 
Portal Venous Thrombosis (PVT)
A common indication for Y90-SIRT is HCC patients 
with portal venous thrombosis (PVT), which develops in 
approximately one third of all patients with unresectable 
HCC (24). Y90-SIRT causes minimal occlusion of the hepatic 
arteries, and it is therefore safe in the setting of PVT (16). 
Kulik et al. (24) conducted the first large-series analysis 
investigating the use of Y90-SIRT in the setting of PVT. 
The phase II study analyzed Y90-SIRT in 108 HCC patients 
with and without PVT (34% versus 66%, respectively) 
and reported partial response rates of 42.4% (size) and 
70% (necrosis) (24). Patient survival varied according to 
the presence of cirrhosis and location of PVT. A phase II 
study conducted by Mazzaferro et al. (47), which assessed 
the efficacy of Y90-SIRT in patients with intermediate or 
advanced HCC, reported that the median time to progression 
(TTP) was 11 months with no significant difference between 
PVT versus no PVT (7 months vs. 13 months, respectively), 
median overall survival was 15 months with a nonsignificant 
trend in favor of patients without PVT (18 months) versus 
with PVT (13 months), objective response was 40.4%, and 
mortality at 30–90 days was 0–3.8%. 
In 2010, the study by Salem et al. (46) confirmed the 
positive outcomes of Y90-SIRT in the treatment of 291 
patients with HCC. This was a single-center, prospective, 
longitudinal cohort study that investigated long-term 
outcomes, response rate (size and necrosis), TTP and 
survival stratified by Child-Pugh, United Network for Organ 
Sharing (UNOS), and Barcelona Clinic Liver Cancer. Survival 
times differed between patients: Child-Pugh A (17.2 
months), Child-Pugh B (7.7 months), and Child-Pugh B with 
PVT (5.6 months). The overall TTP was 7.9 months. TTP was 
longer for Child-Pugh A and B without PVT (15.5 months 
versus 13 months, respectively) in comparison to those with 
PVT (5.6 months versus 5.9 months, respectively) (46). The 
30-day mortality rate was 3% and the response rates were 
57% and 42% based on EASL and WHO criteria, respectively 
(46). That same year, a European study by Hilgard et al. (43) 
analyzed Y90-SIRT in 108 patients with advanced HCC and 
confirmed its safety and efficacy. TTP was 10.0 months with 
an overall survival of 16.4 months. They observed complete 
and partial response by necrosis criteria in 3% and 37%, 
respectively. 
Lobar or Segmental Biliary Tract Obstruction
Yttrium-90 Selective Internal Radiation Therapy has been 
reported to be safe in patients with lobar or segmental 
biliary tract obstruction and normal bilirubin levels (2 mg/
dL or lower) (48). A retrospective study of 12 patients, with 
a median overall follow-up time of 22.9 months, showed 
no evidence of therapy-related progressive leukocytosis, 
bilirubin increase, or biliary complications (infection, 
sepsis, biliary necrosis/stricture, abscess, or biloma 
formation) after Y90-SIRT (48).
 
Novel Concepts
The use of Y90-SIRT has led to the discovery of several 
novel concepts which may help patients who are undergoing 
potentially curative resection (49, 50). One of them is the 
controversial downstaging as a bridge to liver resection or 
transplantation in selected candidates (16, 51-54). Kulik et 
al. (55) reported that following Y90-SIRT, 19 of 34 (56%) 
patients were successfully downstaged from UNOS T3 to 
T2, and of these patients, eight (23%) underwent liver 
transplantation. Lewandowski et al. (56) concluded that 
Y90-SIRT outperforms TACE in downstaging HCC in patients 
from UNOS T3 to T2 (58% versus 31%, respectively). Y90-
SIRT has been shown to be a safe and effective treatment 
for patients with unresectable HCC and transjugular 
intrahepatic portosystemic shunt (TIPS) who are awaiting 
liver transplantation. In the study by Donahue et al. (57), 
six of 12 patients with existing TIPS underwent liver 
transplantation after Y90-SIRT. Ibrahim et al. (58) reported 
that Y90-SIRT appears to be a feasible, safe and effective 
treatment option for patients with unresectable caudate 
lobe HCC and had the potential to downstage. Eight out of 
291 patients were downstaged to within transplantation 
criteria. Four patients (50%) were downstaged from UNOS 
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Table 3. Summary of Clinical Outcomes of Studies of Y90-SIRT (Glass Microspheres) for Treatment of HCC
Lead Author, Year Study Design n Treatment Prognostic Group RR
Median TTP 
(Months)
Median Survival, 
Months (P)
Comparative studies
Moreno-Luna,  
  2013 (63)
Retrospective,  
  non-randomized
116 TheraSphere vs.  
  TACE
15.0 vs. 14.4  
  (0.47)
61 TheraSphere CR 12%ǁ, PR 39%ǁ NR 15.0
  BCLC A
  BCLC B
  BCLC C
NR
NR
NR
NR
NR
NR
23.9 (0.04)
16.8 (0.16)
8.4 (0.47)
55 TACE CR 4%ǁ, PR 47%ǁ NR 14.4
  BCLC A
  BCLC B
  BCLC C 
NR
NR
NR
NR
NR
NR
18.6
13
10.1
Salem,  
  2011 (45)
Retrospective,  
  non-randomized
245 TheraSphere vs.  
  TACE
49%* vs. 36%*  
  (0.104) 
13.3 vs. 8.4  
  (0.046)
20.5 vs. 17.4  
  (0.23)
123 TheraSphere 49%* 13.3 20.5
  BCLC A
  BCLC B
  BCLC C
47%* (0.229)
51%* (0.581)
54%* (0.097)
25.1 (0.4)
13.3 (0.047)
13.8 (0.38)
27.3 (0.74)
17.2 (0.42)
22.1 (0.04)
122 TACE 36%* 8.4 17.4
  BCLC A
  BCLC B
  BCLC C
32%*
44%*
17%*
8.8
9.4
7.9
45.4
17.5
9.3
Lance,  
  2011 (62)
Retrospective,  
  non-randomized
73 TACE vs.  
  SIR-Spheres or  
  TheraSphere
8.0 vs. 10.3 (0.33)
38 SIR-Spheres or  
  TheraSphere
NR NR 8.0 
35 TACE NR NR 10.3
El Fouly,  
  2015 (64)
Prospective,  
  non-randomized
86 TheraSphere vs.  
  TACE
13.3 vs. 6.8 (NS) 16.4 vs. 18 (NS)
44 TheraSphere
  BCLC B
CR 7%ǁ, PR 68%ǁ 13.3 16.4
42 TACE 
  BCLC B
CR 5%ǁ, PR 45%ǁ 6.8 18
Carr,  
  2010 (76)
Retrospective,  
  non-randomized
790 TheraSphere vs.  
  TACE
11.5 vs. 8.5  
  (< 0.05)
99 TheraSphere
  +PVT
  -PVT
CR 3%*, PR 33%* NR 11.5
5 (< 0.05)
16 (NS)
691 TACE
  +PVT
  -PVT
CR 5%*, PR 55%* NR 8.5
7
12
Lewandowski,  
  2009 (56)
Retrospective,  
  non-randomized
86 TheraSphere vs.  
  TACE
41.6 vs. 19.2  
  (0.008)
43 TheraSphere
  UNOS T3
61%* 33.3 41.6
43 TACE
  UNOS T3
37%* 18.2 19.2
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Table 3. Summary of Clinical Outcomes of Studies of Y90-SIRT (Glass Microspheres) for Treatment of HCC (Continued)
Lead Author, Year Study Design n Treatment Prognostic Group RR
Median TTP 
(Months)
Median Survival, 
Months (P)
Woodall,  
  2009 (77)
Prospective,  
  non-randomized
52 TheraSphere NR NR 13.9 vs. 3.2 (0.01)
20 BCLC A-C 
  -PVT
NR NR 13.9
15 BCLC C
  +PVT
NR NR 3.2 (0.26)
17 No treatment,  
  screen failure
NR NR 5.2
Goin,  
  2004 (78)
Retrospective,  
  non-randomized
63 TheraSphere vs.  
  TACE
NR NR NR
34 TheraSphere
  + Okuda I
NR NR 25.5
TheraSphere
  + Okuda II
NR NR 10.9
29 TACE
  + Okuda I
NR NR 11.3
TACE
  + Okuda II
NR NR 11.7
Non-comparative studies
Dancey,  
  2000 (79)
Retrospective, 
  non-randomized  
20 TheraSphere Okuda I/II CP 5%, PR 15% 10.2 12.5
Carr,  
  2004 (34)
Retrospective,  
  non-randomized
65 TheraSphere PR 38.4% NR 21 vs. 10 (NS)
42 Okuda I NR NR 21
23 Okuda II NR NR 10
Geschwind,  
  2004 (80)
Retrospective,  
  non-randomized
80 TheraSphere NR NR 20.6 vs. 12.6  
  (0.02)
54 Okuda I NR NR 20.6
26 Okuda II NR NR 12.6
Goin, 
  2005 (81)
Combined prospective  
  and retrospective,  
  non-randomized  
121 TheraSphere NR NR 15.5 vs. 3.6  
  (< 0.0001)
88 Low risk NR NR 15.5
33 High risk NR NR 3.6
Kulik,  
  2006 (55)
Retrospective,  
  non-randomized  
35 TheraSphere UNOS T3 50%* NR 26.3
Goin,  
  2005 (82) 
Retrospective,  
  non-randomized
88 TheraSphere NR NR (< 0.001)
26 CLIP 0 NR NR 26.7
41 CLIP 1–2 NR NR 11.6
13 CLIP > 2 NR NR 7.1
Salem,  
  2004 (23)
Retrospective,  
  non-randomized  
15 TheraSphere +Branch PVT NR NR 7.1
Pressiani,  
  2013 (69)
Prospective,  
  non-randomized  
297 Sorafenib NR 4.1 9.1
234 BCLC B/C
  CPA
NR 4.2 10.0 (< 0.001)
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Table 3. Summary of Clinical Outcomes of Studies of Y90-SIRT (Glass Microspheres) for Treatment of HCC (Continued)
Lead Author, Year Study Design n Treatment Prognostic Group RR
Median TTP 
(Months)
Median Survival, 
Months (P)
63 BCLC B/C
  CPB
NR 3.8 3.8
Bruix,  
  2012 (68)
Subgroup Study of  
  Prospective Phase III
299 Sorafenib vs. 
  Placebo
6.9 vs. 4.9 14.5 vs. 9.7
54 BCLC B NR 6.9 14.5
245 BCLC C NR 4.9 9.7
Llovet,  
  2008 (66)
Prospective  
  Phase III
602 Sorafenib vs.  
  Placebo
5.5 vs. 2.8  
  (< 0.001)
10.7 vs. 7.9  
  (< 0.001)
299 Sorafenib
  BCLC B + C
PR 2%‡ 5.5 10.7 
303 Placebo
  BCLC B + C
PR 1%‡ 2.8 7.9
Cheng,  
  2009 (67)
Prospective  
  Phase III
226 Sorafenib vs.  
  Placebo
2.8 vs. 1.4  
  (0.005)
6.5 vs. 4.2  
  (0.014)
150 Sorafenib
  BCLC C, CPA
PR 5%‡ 2.8 6.5
76 Placebo
  BCLC C, CPA
PR 1%‡ 1.4 4.2
Mazzaferro,  
  2013 (47)
Prospective  
  Phase II
52 TheraSphere OR 40.4%* 11 15
17 -PVT
  BCLC B
  CPA
OR 8%*
OR 6%*
13
13
 
18
18
35 +PVT
  BCLC C
  CPA
  CPB
OR 13%*
OR 10%*
OR 3%*
7
6
NR
13
16
6
Salem,  
  2010 (46)
Prospective,  
  non-randomized  
291 TheraSphere 42%* 7.9 NR
BCLC A 21%* 25.1 26.9
BCLC B 42%* 13.3 13.3
BCLC C, -EHD 40%* 6.0 7.3
BCLC C, +EHD 11%* 3.1 5.4
Hilgard,  
  2010 (43)
Retrospective,  
  non-randomized  
108 TheraSphere CR 3%‡¶,  
  PR 20%‡¶
10.0 16.4
2
51
55
BCLC A
BCLC B
BCLC C
NR
NR
NR
NR
NR
NR
NR
16.4
NR
CPA
CPB
NR
NR
NR
NR
17.2
6
-PVT
+PVT
NR
NR
NR
NR
16.4
10.0
Kulik,  
  2008 (24)
Prospective  
  Phase II
108 TheraSphere PR 42.4%*,  
  RR 70%†
NR (0.0052)
71 BCLC C, -PVT NR NR 15.4 
25 BCLC C,  
  +Branch PVT
NR NR 10.0
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T3 to T2, three patients underwent liver transplantation, 
and one of the patients despite being downstaged was 
unable to undergo transplantation, given the comorbid 
conditions. Moreover, downstaging can also be achieved in 
patients with PVT (59).
A second novel concept termed “radiation lobectomy” is 
observed in HCC patients whose right-lobe disease is treated 
with Y90-SIRT (16, 49, 50). After Y90-SIRT treatment, the 
irradiated lobe undergoes atrophy and the contralateral 
lobe undergoes hypertrophy, as opposed to portal vein 
embolization which can induce hypertrophy but does not 
treat HCC (16, 60). 
The third novel concept is labeled “radiation 
segmentectomy” and it uses Y90-SIRT to obliterate small, 
single tumor-bearing liver segments that are contraindicated 
for ablation or resection secondary to location, insufficient 
liver reserve, and comorbidities (35, 61). 
Y90-SIRT with Glass Microspheres versus TACE  
in Intermediate Stage HCC
Transarterial chemoembolization is the treatment of 
choice for patients with intermediate stage HCC, but studies 
have shown that Y90-SIRT may have a role in subgroups of 
these patients (16). It is difficult to perform randomized 
controlled trials comparing TACE versus Y90-SIRT. 
In comparison to Y90-SIRT, TACE involves premedicating 
patients (i.e., antibiotics, antiemetics, and narcotics) and 
hospitalization ranging from 1 to 5 days following treatment 
for post-embolization syndrome (16). Moreover, prospective 
data comparing the efficacy with regard to response and/
or survival between Y90-SIRT and TACE in patients with 
intermediate HCC are lacking. 
In 2011 Salem et al. (45) published a large comparative 
effectiveness study. The retrospective study of 245 patients 
who received either TACE (122 patients) or Y90-SIRT (123 
patients), reported that although TTP was longer after 
Y90-SIRT than after TACE (13.3 months versus 8.4 months, 
respectively, p = 0.046), median survival times were not 
statistically different between the two treatment groups in 
patients with intermediate disease (17.2 months versus 17.5 
months, respectively, p = 0.42) (45). Another retrospective 
study showed there was no significant difference in survival 
between Y90-SIRT and TACE (median 8 months versus 10.3 
months, respectively, p = 0.33) (62). This study further 
showed that post-embolization syndrome was significantly 
more severe in patients who underwent TACE resulting in 
increased total hospitalization rates (62).
The retrospective case-control study by Moreno-Luna 
et al. (63) in 2013 showed that there was no significant 
difference in efficacy between Y90-SIRT and TACE. The 
median survival did not differ between Y90-SIRT (15.0 
months) and TACE (14.4 months). The two-year survival 
was 30% for Y90-SIRT and 24% for TACE. Complete tumor 
response was more common after Y90-SIRT (12%) than 
after TACE (4%). However, Y90-SIRT patients reported more 
fatigue, had less fever and required less hospitalization than 
patients treated with TACE. The study by El Fouly et al. (64) 
in 2014 reported similar findings during the comparative 
analysis between TACE and Y90-SIRT in the treatment of 
86 patients with intermediate stage HCC. Both treatments 
resulted in similar median overall survival rates (18 months 
for TACE versus 16.4 months for Y90-SIRT) and the TTP was 
not statistically different between treatments. However, the 
number of treatment sessions, total hospitalization time, 
and rate of adverse events were significantly higher in the 
TACE cohort. Future studies comparing Y90-SIRT and TACE 
Table 3. Summary of Clinical Outcomes of Studies of Y90-SIRT (Glass Microspheres) for Treatment of HCC (Continued)
Lead Author, Year Study Design n Treatment Prognostic Group RR
Median TTP 
(Months)
Median Survival, 
Months (P)
12 BCLC C,  
  +Main PVT
NR NR 4.4
Salem,  
  2005 (11)
Prospective  
  Phase II
43 TheraSphere PR 47% NR 24.4 vs. 12.5  
  (< 0.001)
21 Okuda I NR NR 24.4
22 Okuda II NR NR 12.5
*WHO criteria, †EASL criteria, ‡RECIST criteria, ǁmRECIST criteria (30), ¶76 out of 108 responses + necrosis after 30 days of treatment. 
BCLC = Barcelona Clinic Liver Cancer staging system, CLIP = Cancer of the Liver Italian Program scoring system, CP = Child-Pugh score, CR 
= complete response, -EHD/+EHD = without or with extrahepatic disease, HCC = hepatocellular carcinoma, NR = not recorded, NS = not 
statistically significant, OR = objective response, PR = partial response, PVT = portal vein thrombosis, RR = response rate, SIRT = selective 
internal radiation therapy, TACE = transarterial chemoembolization, TTP = time to progression, UNOS = United Network for Organ Sharing, 
Y90 = yttrium-90
483
Y90-SIRT for HCC Treatment
Korean J Radiol 17(4), Jul/Aug 2016kjronline.org
Table 4. Summary of Ongoing and Recruiting Clinical Trials for Y90-SIRT for HCC Treatment (6) 
Clinical Trials.gov 
Identifier
Treatment Arm(s)
Patient 
Population
Primary Outcome Measure Status Sponsor
NCT01349075 TheraSphere  
  (Yttrium-90)
Unresectable  
  HCC
Response to treatment via  
  diagnostic imaging
Recruiting Thomas Jefferson  
  University
NCT02072356 TheraSphere  
  (Yttrium-90)
Unresectable  
  HCC
Response to treatment;  
  survival time, adverse  
  experiences
Recruiting Ohio State University  
  Comprehensive Cancer  
  Center
NCT00906984 TheraSphere  
  (Yttrium-90)
Unresectable  
  HCC
Response to treatment via  
  diagnostic imaging
Recruiting University of California,  
  Irvine
NCT01176604 TheraSphere  
  (Yttrium-90)
Unresectable  
  HCC
Overall survival associated  
  with treatment
Recruiting M.D. Anderson Cancer  
  Center
NCT00877136 TheraSphere  
  (Yttrium-90)
Unresectable  
  HCC
Evaluate patient quality of  
  life and toxicities associated 
  with treatment
Recruiting St. Joseph Hospital of  
  Orange
NCT01686880† SIR-Spheres 
  (Yttrium-90)
HCC in  
  cirrhotic liver
Peri-operative morbidity  
  of SIRT prior to surgical  
  resection or radiofrequency 
Recruiting Jules Bordet Institute
NCT00956930† Yttrium-90 glass  
  microspheres vs. TACE  
  (cisplatin, mitomycin,  
  doxorubicin)
Unresectable  
  HCC
Time to progression in  
  patients treated with  
  TACE vs. Y90 via diagnostic  
  imaging
Recruiting Northwestern University
NCT01381211† TheraSphere  
  (Yttrium-90) vs.  
  TACE-DEB (doxorubicin)
Intermediate  
  HCC
Time to progression Recruiting University Hospital, Ghent
NCT00846131* TheraSphere  
  (Yttrium-90) vs.  
  Sorafenib + TheraSphere  
  (Yttrium-90)
Pre-transplant  
  HCC
Evaluate sorafenib as an  
  adjunct to Y-90 for control  
  of HCC as a bridge/ 
  downstage to transplant
Ongoing Northwestern University
NCT01900002† TheraSphere (Yttrium-90)  
  + Sorafenib
Advanced HCC Toxicity of Sorafenib and  
  Yttrium-90
Recruiting M.D. Anderson Cancer  
  Center
NCT01556490‡ Sorafenib vs. TheraSphere  
  (Yttrium-90) + Sorafenib
Unresectable  
  HCC
Overall survival Recruiting BTG International Inc.
NCT01126645† RFA followed by sorafenib  
  or placebo (local  
  ablation group) or SIRT  
  + sorafenib or sorafenib  
  alone (palliative  
  treatment group)
Unresectable  
  HCC
Time to recurrence; overall  
  survival; Primovist®- 
  enhanced MRI is non- 
  inferior or superior  
  compared with contrast- 
  enhanced multislice CT
Recruiting University of Magdeburg
NCT01482442‡ SIR-Spheres 
  (Yttrium-90) vs.  
  Sorafenib
Advanced HCC Median overall survival time Recruiting Assistance Publique -  
  Hôpitaux de Paris
NCT01135056‡ SIR-Spheres 
  (Yttrium-90) vs.  
  Sorafenib
Locally  
  advanced HCC
Overall survival Recruiting Singapore General Hospital
NCT02004210‡ TACE vs. TARE Advanced HCC Overall survival Recruiting Seoul National University  
  Hospital
NCT00530010 TheraSphere (Yttrium-90) Unresectable  
  HCC
Proportion of patients  
  completing scheduled  
  treatment plan
Recruiting Northwestern University
484
Lee et al.
Korean J Radiol 17(4), Jul/Aug 2016 kjronline.org
should also assess their cost-effectiveness in therapy for 
intermediate stage HCC, given the increased hospital stay 
due to complications from repeated TACE treatments. 
Although studies have not shown statistically significant 
differences in efficacy or survival between Y90-SIRT and 
TACE, Y90-SIRT seems to be better tolerated with significant 
differences in length of hospital stay and post-embolization 
symptoms. In addition, Y90-SIRT outperforms TACE with 
regard to downstaging and quality of life measures. As 
discussed previously, the ability to downstage from UNOS T3 
to T2 as a bridge to liver transplantation was achieved more 
frequently with Y90-SIRT (58%) than with TACE (31%) (56). 
In 2013, the study by Salem et al. (65) demonstrated that 
Y90-SIRT outperformed TACE by validated quality-of-life 
(QoL) measures. The prospective study of 56 patients with 
HCC who underwent Y90-SIRT versus TACE (29 versus 27, 
respectively) showed that although patients who received 
Y90-SIRT had a larger tumor burden, they had higher QoL 
scores in comparison to patients who received TACE.
Y90-SIRT with Glass Microspheres versus Sorafenib  
in Advanced Stage HCC 
The treatment of choice in patients with advanced stage 
HCC is sorafenib and it is associated with an overall survival 
of 6.5–14.5 months (43, 66-69). It is difficult to compare 
the efficacy of Y90-SIRT with sorafenib in advanced HCC 
through well-designed randomized controlled studies, given 
the high probability of crossover among treatment groups 
as HCC progresses. No study directly comparing sorafenib 
with Y90-SIRT with glass microspheres is currently available. 
However, the observational cohort study by Hilgard et al. 
(43) showed that in comparison to the phase III trial which 
led to the approval of sorafenib (SHARP trial), the median 
overall survival in patients with advanced HCC treated with 
Y90-SIRT was slightly longer (16.4 months) than that in 
patients with advanced HCC treated with sorafenib (10.7 
months) (66). In addition, unlike Y90-SIRT, sorafenib has 
been shown to have significant side effects, which result 
in treatment discontinuation (44%), dose reduction, or 
withdrawal (64%) (66, 69). 
Future Prospects 
There are currently 16 active clinical trials investigating 
the use of Y90-SIRT with glass microspheres for treatment 
of HCC (Table 4) (6). In the United States, there are 
studies investigating the use of Y90-SIRT for the treatment 
of unresectable HCC (NCT01349075, NCT02072356, 
NCT00906984, NCT01176604, and NCT00877136) 
and assessing the safety of Y90-SIRT compared to 
radiofrequency prior to surgical resection in patients 
with HCC (NCT01686880) (6). The PREMIERE trial in the 
United States is comparing Y90-SIRT with TACE in patients 
who are not candidates for radiofrequency ablation or in 
patients with unresectable HCC (NCT00956930) (6). The 
European TRACE trial is a multicenter randomized control 
study comparing TARE with TACE for the treatment of HCC 
(NCT01381211) (6). 
The good toxicity profile of Y90-SIRT makes it an 
alternative or adjunct to treatment with sorafenib (70). 
Table 4. Summary of Ongoing and Recruiting Clinical Trials for Y90-SIRT for HCC Treatment (6) (Continued)
Clinical Trials.gov 
Identifier
Treatment Arm(s)
Patient 
Population
Primary Outcome Measure Status Sponsor
NCT02305459 TheraSphere (Yttrium-90)  
  + QLQ-C30 with HCC  
  module (Behavorial)
HCC Change from Baseline in  
  Quality of Life questionnaire 
  QLQ-C30 with HCC Module
Recruiting Cardiovascular and  
  Interventional  
  Radiological Society of  
  Europe
NCT01775280† Yttrium-90 glass  
  microspheres
Unresectable  
  to borderline  
  resectable  
  HCC
Percentage of patients  
  that can be downstaged to  
  resectability
Recruiting University of Zurich
NCT01798160ǁ TACE-DEB vs. SIR-Spheres 
  (Yttrium-90)
HCC Progression-free survival;  
  overall survival
Ongoing Johannes Gutenberg  
  University Mainz
NCT01887717‡ TheraSphere (Yttrium-90)  
  vs. Sorafenib
Advanced HCC  
  with PVT
Overall survival Recruiting BTG International Inc.
*Phase I trials, †Phase II trials, ‡Phase III trials, ǁPhase IV trials. DEB = drug eluting beads, HCC = hepatocellular carcinoma, PVT = portal 
vein thrombosis, RFA = radiofrequency ablation, SIRT = selective internal radiation therapy, TACE = transarterial chemoembolization, TARE 
= transarterial radioembolization
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In the United States, a prospective randomized trial is 
studying the role of Y90-SIRT alone or in combination 
with sorafenib in the treatment of HCC patients who are 
awaiting liver transplantation (NCT00846131) and a phase 
II study is investigating the role of Y90-SIRT with sorafenib 
in advanced HCC (NCT01900002) (6). The STOP-HCC 
study, which is being conducted in the United States and 
Europe, is comparing sorafenib with and without Y90-SIRT 
(NCT01556490) (6). The outcomes of these trials may result 
in the incorporation of Y90-SIRT with glass microspheres 
into the treatment guidelines as a standard therapy option 
for patients with intermediate and advanced stage HCC.
CONCLUSION
Although the use of Y90-SIRT in treating liver 
malignancies dates back to the 1960s (71-73), it has 
recently begun to gain clinical acceptance as a promising 
treatment option for patients with intermediate and 
advanced HCC (8). Multiple studies have provided 
compelling data which suggest that Y90-SIRT in 
comparison to TACE, has a higher tumor response, less post-
embolization symptoms, better downstaging outcomes, and 
provides a higher QoL. However, the EASL, the European 
Organization for Research and Treatment of Cancer, and the 
American Association for the Study of Liver Diseases do not 
currently recommend Y90-SIRT as a standard therapy for 
intermediate or advanced HCC outside clinical trials (70). 
This clinical lack of enthusiastic approval stems from the 
fact that there is a lack of research and evidence from large-
scale randomized controlled trials. Nonetheless, with the 
growing body of level 2 and level 3 evidence, Y90-SIRT has 
found a place in the guidelines adopted by the European 
Society for Medical Oncology, the European Society of 
Digestive Oncology, and the National Comprehensive Cancer 
Network (21). Y90-SIRT may become widely accepted and 
may be incorporated into the treatment guidelines if further 
research shows reproducibility, multicenter implementation, 
and economic feasibility. 
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